GlassScriptPhysician profile
Samuel G Walker
NPI 1144727579
$755.74
in general payments reported to CMS, 2019-2025
14 companies · $198 in 2025
The $198 reported for 2025 was more than what 76% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.56 · 2022: $92.68 · 2023: $168 · 2024: $259 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $138.91 | 2022-2025 | Lifevest |
| Pfizer INC. | $120.33 | 2022-2024 | |
| Abbvie INC. | $79.78 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $61.48 | 2022-2024 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $55.82 | 2020-2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $55.77 | 2022-2024 | Dificid, Zerbaxa, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $46.68 | 2025 | Eliquis |
| Dexcom, INC. | $43.89 | 2024-2025 | Dexcom G6 Transmitter |
| La Jolla Pharmaceutical Company | $40.70 | 2023 | Xerava |
| Vertex Pharmaceuticals Incorporated | $38.43 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.55 | 2023 | Xifaxan |
| Daxor Corporation | $21.56 | 2024 | Bva-100 |
| Janssen Pharmaceuticals, INC | $17.40 | 2024 | Xarelto |
| Mylan Specialty L.P. | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.